- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Redwood City Today
By the People, for the People
Pliant Therapeutics Reports Q1 Earnings Beat
Biotech firm exceeds analyst expectations despite ongoing challenges
Mar. 11, 2026 at 9:07pm
Got story updates? Submit your updates here. ›
Pliant Therapeutics (NASDAQ:PLRX), a clinical-stage biopharmaceutical company focused on fibrotic diseases, reported its first quarter 2026 earnings results on Wednesday. The company reported a loss of $0.38 per share, exceeding the consensus analyst estimate of a $0.44 per share loss.
Why it matters
Pliant Therapeutics has faced headwinds in recent quarters, with its stock price declining over the past year. However, this earnings beat suggests the company may be making progress in its drug development efforts, which could be a positive sign for investors.
The details
Pliant reported a net loss of $23.4 million for the quarter, an improvement over the $26.9 million loss in the same period a year earlier. The company cited continued progress with its lead drug candidate PLN-74809, which is in clinical trials for idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC).
- Pliant Therapeutics reported its Q1 2026 earnings results on Wednesday, March 11, 2026.
The players
Pliant Therapeutics
A clinical-stage biopharmaceutical company focused on developing therapies for fibrotic diseases.
PLN-74809
Pliant's lead drug candidate, an oral small molecule designed to inhibit integrins involved in fibrosis.
What they’re saying
“We must continue to execute on our clinical programs and advance our pipeline of novel fibrosis therapies.”
— Bernard Coulie, CEO, Pliant Therapeutics (Pliant Therapeutics earnings call)
What’s next
Pliant Therapeutics plans to provide an update on its clinical trials for PLN-74809 in the coming months.
The takeaway
While Pliant Therapeutics has faced challenges, this earnings beat suggests the company may be making progress in its efforts to develop new treatments for fibrotic diseases. Investors will be closely watching for further updates on the company's pipeline.
